West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.

West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.

West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.

WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.

West Pharmaceuticals stock moved higher following another quarter of broad-based growth, driven by continued demand for high-value biologics packaging and proprietary delivery components. Tyler Technologies underperformed during the quarter despite delivering solid financial results that met management's guidance. We were attracted to Knowles' accelerating organic growth, expanding margins, and exposure to several attractive long-term secular trends.

Dimensional Fund Advisors LP lifted its stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 5.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 461,462 shares of the medical instruments supplier's stock after acquiring an additional 24,102 shares during

Bank of Nova Scotia increased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 337.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,323 shares of the medical instruments supplier's stock after buying an additional 50,402 shares

West Pharmaceutical Services delivered a strong 2Q26, beating on both revenue ($872.3M, +13.8% YoY) and EPS ($2.37, +$0.29 vs. consensus). WST raised full-year guidance to $3.345–$3.380B in sales and $8.85–$9.05 in EPS, reflecting confidence in sustained double-digit organic growth and margin expansion. High-Value Product components and biologics drove mix shift, with HVP now 49% of revenue and biologics up 29% organically, supporting durable margin gains.

West Pharmaceutical Services NYSE: WST raised its full-year 2026 outlook after reporting second-quarter results that topped management's expectations, supported by strong demand for high-value product components, biologics-related offerings and GLP-1 elastomers.